期刊
EPILEPSIA
卷 54, 期 -, 页码 25-29出版社
WILEY
DOI: 10.1111/epi.12439
关键词
Biomarker; Epilepsy; Brain tumor; O-6-methylguanine methyltranferase; Isocitrate dehydrogenase 1; Isocitrate dehydrogenase 2; Long-term epilepsy associated tumors; Glioma-CpG island DNA methylator phenotype
资金
- Case Comprehensive Cancer Center Support Grant [NIH/NCI P30 CA043703]
Gene markers or biomarkers can be used for diagnostic or prognostic purposes for all different types of complex disease, including brain tumors. Prognostic markers can be useful to explain differences not only in overall survival but also in response to treatment and for development of targeted therapies. Multiple genes with specific types of alterations have now been identified that are associated with improved response to chemotherapy and radiotherapy, such as O-6-methylguanine methyltranferase (MGMT) or loss of chromosomes 1p and/or 19q. Other alterations have been identified that are associated with improved overall survival, such as mutations in isocitrate dehydrogenase 1 (IDH1) and/or isocitrate dehydrogenase 2 (IDH2) or having the glioma CpG island DNA methylator phenotype (G-CIMP). There are many biomarkers that may have relevance in brain tumor-associated epilepsy that do not respond to treatment. Given the rapidly changing landscape of high throughput omics technologies, there is significant potential for gaining further knowledge via integration of multiple different types of high genome-wide data. This knowledge can be translated into improved therapies and clinical outcomes for patients with brain tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据